Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA
Phase III Studies: Confirmation of Efficacy safety and of HMPL-523 in Adult Patients With wAIHA
Phase II Study: the proportion of patients with overall Hb response by Week 24
Phase III study: the proportion of patients who achieve a durable response by Week 24
| Condition | Warm Antibody Autoimmune Hemolytic Anemia |
|---|---|
| Treatment | Placebo, HMPL-523(300mg PO QD) |
| Clinical Study Identifier | NCT05535933 |
| Sponsor | Hutchison Medipharma Limited |
| Last Modified on | 29 July 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.